share_log

Therma Bright Announces Quantify Medical as Nationwide U.S. Distribution Partner From August 22, 2024 Press Release

Therma Bright Announces Quantify Medical as Nationwide U.S. Distribution Partner From August 22, 2024 Press Release

Therma Bright宣佈Quantify Medical成爲2024年8月22日新聞發佈會上的全美分銷合作伙伴
newsfile ·  10/10 18:30

Quantify Medical Sees Initial Success with Venowave VW5 Sales and Medicare/Medicaid Reimbursement Test

Quantify Medical在Venowave VW5銷售和Medicare/Medicaid報銷測試中取得了初步成功

Therma Bright Closes First Tranche of Non-Brokered Concurrent Private Placement for CAD $174,900

Therma Bright完成首筆非經紀同時定向增發,金額爲174,900加拿大元

Toronto, Ontario--(Newsfile Corp. - October 10, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner in a wide range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that its nationwide U.S. medical device distribution partner as Quantify Medical as previously announced on August 22, 2024. Quantify Medical has witnessed promising preliminary success with its Venowave VW5 device sales and Medicare/Medicaid reimbursement program, which was established to test timelines and billing procedures.

多倫多,安大略省--(Newsfile corp.--2024年10月10日)--Therma Bright公司(tsxv: THRM)(OTCQB: TBRIF)(FSE: JNX)("Therma" 或 "公司"),是一家開發和投資合作伙伴從事廣泛領先的專有診斷和醫療器械技術的公司,高興宣佈其全美醫療器械流通合作伙伴Quantify Medical如前述於2024年8月22日宣佈的一樣。Quantify Medical在其Venowave VW5器械銷售和Medicare/Medicaid報銷計劃中取得了令人鼓舞的初步成功,該計劃旨在測試時間表和賬單程序。

Following the conclusion of the test, Quantify Medical looks to acquire the remaining Venowave VW5 inventory. If all inventory were to be purchased by the distributor it would represent up to USD $2.38M in HCPCS Level II code E068 reimbursement. In August 2024, the Venowave VW5 was the first device of its kind to receive permanent Medicare and Medicaid HCPCS Level II code, which qualifies for reimbursement for ten (10) indications.

在測試結束後,Quantify Medical希望收購剩餘的Venowave VW5庫存。如果所有庫存都被分銷商購買,將可以獲得高達238萬美元的HCPCS Level II E068編碼報銷。2024年8月,Venowave VW5是首款獲得永久Medicare和Medicaid HCPCS Level II編碼的裝置,有資格獲得10種指示的報銷。

"We are thrilled with the initial results of our Venowave VW5 device sales and the speed and efficiency of Medicare and Medicaid processing the HCPCS Level II code reimbursements," shared Justin Goldston, President of Quantify Medical. "We expect great results when we conclude this initial test with our provider network and look forward to a successful partnership with Rob and Therma Bright with Venowave."

"我們對Venowave VW5器械銷售的初步結果以及Medicare和Medicaid處理HCPCS Level II編碼報銷速度和效率感到非常高興,"Quantify Medical董事長Justin Goldston分享道。"我們期待在與我們的供應商網絡結束這一初步測試時取得出色的成績,期待與Rob和Therma Bright攜手取得成功。"

Rob Fia, CEO of Therma Bright commented: "We are excited to announce Quantify Medical as our nationwide U.S. distribution partner and the initial success Quantify Medical has experienced with the Medicare/Medicaid reimbursement test. It has been a pleasure to work with Justin and his team and we look forward to providing updates on Quantify Medical's next Venowave sales milestones."

Therma Bright首席執行官Rob Fia評論道:"我們很高興宣佈Quantify Medical是我們的全美分銷合作伙伴,以及Quantify Medical在Medicare/Medicaid報銷測試中取得的初步成功。與Justin及其團隊合作非常愉快,我們期待提供關於Quantify Medical下一步Venowave銷售里程碑的更新。"

The Venowave VW5 device is a series of compact, battery-operated peristaltic pumps that generate a wave-form motion. When worn below the knee, strapped firmly to the calf, the device results in compression of the calf and consequently an increased upward volumetric displacement of venous and lymph fluid. The 2-pair unit induces improved vascular and lymphatic flow in the lower limbs. Operating with a single rechargeable 1.5 V NiMh AA battery, this FDA-designated Durable Medical Equipment device enables users to receive treatment anywhere while remaining active. The Venowave VW5 assures it can withstand repeated use by successive patients.

Venowave VW5器械是一系列緊湊的、電池操作的蠕動泵,可產生波形運動。當穿戴在膝蓋以下,緊貼小腿,該器械會壓縮小腿,從而增加下肢靜脈和淋巴液的向上體積位移。這款雙對單位在下肢誘導改善血管和淋巴流動。使用單個可充電的1.5V鎳氫AA電池,這款FDA指定的耐用醫療器械設備使用戶在任何地方接受治療時仍然保持活動。Venowave VW5確保它可以經受連續患者的重複使用。

In addition, Therma announces a first tranche closing of the concurrent non-brokered private placement portion as previously announced on September 27, 2024 Non-Brokered LIFE Financing & Concurrent Private Placement for up to a combined CAD $6 Million (the "Financing").
Under the first tranche of the concurrent non-brokered private placement portion, Therma issued 2,915,000 common shares priced at $0.06 per common share for total proceeds of $174,900 (the "First Tranche"). No finder's fee was paid in connection with the First Tranche. All securities issued under the First Tranche are subject to a hold period expiring February 11, 2025, in accordance with applicable securities laws and the policies of the TSX Venture Exchange (the "TSXV").

此外,Therma宣佈了與之前公佈的2024年9月27日《無經紀人蔘與LIFE融資和同時私募融資》的特許非經紀人私募融資部分的第一筆交易完成。
在特許非經紀人私募融資部分的第一筆交易中,Therma發行了2,915,000股以每股0.06美元的價格發行的普通股,總收益爲174,900美元(「第一筆交易」)。與第一筆交易無關連的佣金未支付。第一筆交易下發行的所有證券均受限於到期日爲2025年2月11日的限制期,根據適用證券法和TSX創業公司交易所(「TSXV」)的政策。

As previously stated, the closing of the concurrent private placement may take place in one or more tranches, as determined by the Company and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the conditional approval from the TSXV.

如前所述,同時私募融資的關閉可能分爲一個或多個階段進行,由公司確定,並受制於諸如收到所有必要批准(包括TSXV的有條件批准)等條件。

Rob Fia, the CEO, President and a director of Therma participated in the First Tranche and purchased 415,000 common shares for $24,900. Mr. Fia's participation in the First Tranche constitutes a "related party transaction" as defined under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions ("MI 61-101"). Such participation is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of the securities that he acquired, nor the consideration for the securities that he paid, exceeded 25% of the Company's market capitalization.

Therma的首席執行官、總裁兼董事Rob Fia參與了第一筆交易,以24,900美元購買了415,000股普通股。Fia先生在第一筆交易中的參與構成了根據《多邊儀61-101》少數股東在特殊交易中的保護的相關交易。按照《MI 61-101》的規定,由於他所獲得的證券的公允市場價值及他支付的證券的對價均未超過公司市值的25%,此類參與免除了MI 61-101關於正式估值和少數股東批准的要求。

The securities acquired by Mr. Fia under the First Tranche are held for investment purposes only. Mr. Fia may acquire additional securities of the Company or dispose of Therma shares (through market or private transaction) from time to time.

Fia先生在首期交易中獲得的證券僅用於投資目的。Fia先生可能不時收購該公司的其他證券,或出售Therma股份(通過市場或私人交易)。

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933 (the "1933 Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as defined in the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration is available.

本新聞稿不構成在美國銷售或購買任何證券的要約。該證券未按照《1933年證券法案》(以下簡稱「1933年法案」)或任何州證券法案進行註冊,且不得在美國境內或向美國人(根據1933年法案的定義)出售或提供,除非依據1933年法案和適用的州證券法規進行註冊或免於註冊。

About Therma Bright Inc.
Therma Bright is a developer and partner in a wide range of leading edge, proprietary diagnostic and medical device technologies focused on providing consumers and medical professionals with quality, innovative solutions that address some of today's most important medical and healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: .

Therma Bright Inc.簡介:Therma Bright是一家開發商和合作夥伴,在各種領先的專有診斷和醫療器械技術方面致力於爲消費者和醫療專業人士提供質量卓越,創新的解決方案,以應對當今最重要的醫療和醫療保健挑戰。在TSXV:THRM,OTCQB:TBRIF,FSE:JNX上交易。訪問:。
Therma Bright Inc.

Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com

Rob Fia,首席執行官
rfia@thermabright.com
rfia@thermabright.com

Follow us on:
Twitter

關注我們的:Twitter、Facebook、LinkedIn、YouTube、Instagram、博客。
推特

FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as future sales of Venowave and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-Looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.

前瞻性聲明
本新聞稿中的某些聲明構成"前瞻性"聲明。這些聲明涉及未來事件,如新聞稿中描述的Venowave及相關技術的未來銷售。所有這些聲明涉及大量已知和未知的風險、不確定性和其他因素,可能導致實際結果與此類前瞻性聲明所表達或暗示的結果有所不同。前瞻性聲明涉及重大風險和不確定性,不應視爲未來業績或結果的保證,也不一定能準確顯示這些結果是否會實現。由於若干因素和風險,實際結果可能大不相同。儘管本新聞稿中包含的前瞻性聲明基於本公司管理層在本新聞稿日期認爲合理的假設,但本公司不能向投資者保證實際結果將與這些前瞻性聲明一致。本新聞稿中包含的前瞻性聲明截至本日發佈,並且本公司否認有任何意向或義務更新或修訂任何前瞻性聲明,除非根據適用的證券法規要求。

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

TSX Venture Exchange及其監管服務提供商(如TSX Venture Exchange政策中所定義)對本新聞稿的充分性或準確性不承擔責任。

Not for distribution to United States newswire services or for dissemination in the United States.

請勿將本文轉讓給美國新聞社或在美國進行傳播。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論